Status:
RECRUITING
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Lead Sponsor:
Scott Silveira
Collaborating Sponsors:
Concordia University Chicago
EGACeutical
Conditions:
Aging
Frailty
Eligibility:
All Genders
60-80 years
Phase:
NA
Brief Summary
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucl...
Detailed Description
This randomized, double-blind, placebo-controlled, two-arm crossover trial will compare the effects of two NAD⁺-modulating interventions-EGA® and conventional nicotinamide mononucleotide (NMN) supplem...
Eligibility Criteria
Inclusion
- Adults aged 60 to 80 years, of any sex
- Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study
- Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing
- Montreal Cognitive Assessment (MoCA) score of 26 or higher
- Free from acute or uncontrolled chronic medical conditions that would pose a risk or interfere with study participation
- Physically capable of engaging in structured exercise involving moderate to vigorous intensity stationary cycling
- Successful completion of a graded exercise test (e.g., stationary bike) without significant adverse events or contraindications
- Ability to attend at least four in-person laboratory visits in Beverly Hills, California
- Non-smoker for at least 12 months
- Able to provide informed consent and comply with study procedures
- Willing to refrain from initiating new exercise, dietary supplement, or medication regimens during the study
Exclusion
- Severe cardiovascular disease (e.g., recent myocardial infarction \<6 months, unstable angina, uncontrolled hypertension \>160/100 mmHg)
- Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation)
- Significant neurological impairments that hinder comprehension of instructions or participation in exercise
- Terminal illness or conditions limiting life expectancy or ability to complete the study
- Severe cognitive impairment preventing informed consent, protocol adherence, or comprehension of interventions
- Significant orthopedic limitations or injuries that prevent safe exercise participation
- Use of NMN, NR, or other NAD+-altering supplements within the past 14 weeks
- Anticipated or current alcohol consumption \>2 drinks per week, or unwillingness to abstain from alcohol during the study
- Current substance abuse affecting study participation or adherence
- Other acute or chronic health conditions judged by the investigators to pose risk or interfere with study objectives
- Non-compliance with study requirements, withdrawal of informed consent, or unforeseen circumstances compromising completion
- Any condition which, in the opinion of the investigator, would interfere with study participation or interpretation of results
Key Trial Info
Start Date :
September 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07144527
Start Date
September 15 2025
End Date
November 1 2026
Last Update
September 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Office of Dr. Robert Huizenga MD
Beverly Hills, California, United States, 90210